查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2026927

Capecitabine市場預測至2034年－按類型、適應症、通路、最終用戶和地區分類的全球分析

Capecitabine Market Forecasts to 2034 - Global Analysis By Type (Generic and Branded), Indication (Breast Cancer, Colorectal Cancer and Other Indications),Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球Capecitabine市場規模將達到 5.331 億美元，並在預測期內以 6.9% 的複合年成長率成長，到 2034 年將達到 9.091 億美元。

抗癌藥物Capecitabine用於治療多種癌症，包括腹部癌症、大腸癌和乳癌。Capecitabine以商品名「Xeloda」（Xeloda）銷售，可作為單藥治療或用於治療轉移性乳癌。在大腸直腸癌的治療中，它主要作為輔助性治療，與放射線治療合併使用。Capecitabine因其療效顯著、副作用相對可控，以及有助於提高多種癌症患者的存活率和生活品質而備受讚譽。

根據美國癌症協會的報告，據估計，2017 年美國約有 135,430 例新的大腸直腸癌病例和 50,260 例死亡病例。

癌症患者數量增加

Capecitabine是一種抗癌藥物，廣泛用於治療多種癌症，包括乳癌、大腸癌和胃癌。它可口服，並在體內轉化為活性形式，使其成為一種非常便捷有效的癌症治療選擇。隨著癌症患者數量的不斷增加，人們對Capecitabine等治療藥物的需求日益成長，這推動了卡培他濱作為對抗全球癌症病例激增的重要治療手段的市場成長。

醫療成本不斷上漲

隨著醫療成本（包括醫療費用）的不斷上漲，成本效益已成為患者和醫療系統的焦點。Capecitabine是一種用於治療多種癌症的抗癌藥物，由於其高成本，可能難以獲得，從而影響患者的治療依從性和醫療預算。個人和醫療機構日益沉重的經濟負擔可能會限制患者獲得該藥物，阻礙其廣泛應用，並影響癌症患者的治療選擇。

口服化療的推廣

與傳統的靜脈化療相比，口服Capecitabine為患者提供了更大的便利性、柔軟性，並能在整個治療過程中提升患者的生活品質。此外，它還簡化了醫療服務流程，減少了患者就診次數，並允許患者在家中自行給藥，從而降低了醫療成本。癌症治療中轉變為口服化療的代表著治療方法的革新。口服Capecitabine引領了這一趨勢，透過滿足患者對更便利、更容易獲得的治療方法方案的需求，確立了強大的市場地位。這有望推動市場成長。

熟練專業人員短缺

化療藥物（包括Capecitabine等）的使用需要專業的知識和訓練。缺乏能夠管理和監督化療流程的腫瘤科醫生、護理師和藥劑師會阻礙Capecitabine的有效使用和處方。這種專業人員的短缺會導致治療品質下降、患者療效受損，並最終限制該藥物的使用。

新冠疫情的影響

新冠疫情對整體經濟造成了重大影響。在此期間，許多原料藥（API）生產廠因疫情關閉，為原料藥產業帶來了許多困難，包括供應鏈中斷、原料和包裝材料採購困難以及人手不足導致的產能下降。然而，隨著新冠疫情的惡化，部分藥品市場需求激增，進而帶動了與生產相關的原料藥需求成長。

在預測期內，乳癌細分市場預計將是規模最大的。

乳癌領域預計佔比最大。Capecitabine是一種口服抗癌藥物，廣泛用於各種階段和類型的乳癌，包括轉移性乳癌和術後輔助性治療。由於其抑制癌細胞增殖的作用以及口服給藥的便利性，Capecitabine是乳癌治療方法中的首選藥物。無論是聯合治療或單藥治療，Capecitabine憑藉其針對乳癌細胞的療效，確立了其在滿足乳癌患者治療需求方面的重要地位。

在預測期內，膠囊劑細分市場預計將呈現最高的複合年成長率。

預計在預測期內，膠囊劑市場將實現顯著成長。Capecitabine通常以膠囊劑型供應，為接受化療的患者提供了一種方便的給藥途徑。膠囊含有活性成分，便於精準給藥和服用。此外，Capecitabine膠囊的市佔率已顯著提升，透過為醫護人員和患者提供便利高效的癌症治療方案，進一步鞏固了其在製藥業的地位。

市佔率最大的地區：

由於亞太地區癌症發生率高且老年人口比例高，該地區在預測期內佔據了最大的市場佔有率。此外，該地區龐大的人口基數，尤其是在中國、印度和日本等國家，造就了大規模的患者群體，推動了市場擴張。同時，製藥公司之間的合作、政府改善癌症治療的舉措以及經濟實惠的學名藥的推出，進一步提高了Capecitabine在全部區域的可及性和分銷範圍。

複合年成長率最高的地區：

在北美，大型學名藥公司的存在、政府主導的各項舉措以及不斷壯大的專業群體預計將在預測期內推動卡培他濱市場實現盈利成長。此外，該地區完善的醫療基礎設施、先進的研究設施以及較高的癌症發病率，也促成了Capecitabine在包括乳癌和大腸癌在內的多種癌症治療中的廣泛應用。有利的報銷政策和不斷成長的醫療保健投資也為Capecitabine的供應提供了支持，使北美成為塑造Capecitabine使用和市場擴張趨勢的關鍵地區。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家和地區的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球Capecitabine市場：依藥物類型分類

  • 非專利的
  • 品牌商品

第6章：全球Capecitabine市場：依適應症分類

  • 乳癌
  • 結腸癌
  • 其他改編

第7章 全球Capecitabine市場：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章：全球Capecitabine市場：以劑型分類

  • 膠囊
  • 藥片

第9章 全球Capecitabine市場：依最終用戶分類

  • 醫院
  • 專業醫療中心
  • 居家照護
  • 其他最終用戶

第10章 全球Capecitabine市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Mylan NV
  • Sanofi
  • GSK plc
  • Pfizer Inc.
  • Novartis AG
  • Lilly
  • Bayer AG
  • Merck & Co., Inc.
  • Aurobindo Pharma
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Labs Ltd
  • Lupin
  • Armas Pharmaceuticals, Inc
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Fresenius SE & Co. KGaA
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Limited
Product Code: SMRC24733

According to Stratistics MRC, the Global Capecitabine Market is accounted for $533.1 million in 2026 and is expected to reach $909.1 million by 2034 growing at a CAGR of 6.9% during the forecast period. A chemotherapy drug called capecitabine is used to treat a variety of cancers, such as abdomen, colorectal, and breast cancers. It is commercialized under the trade name of XelodaCapecitabine is used as a monotherapy or metastatic treatment for breast cancer, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation. It is known for its efficacy, relatively manageable side effects, and its role in improving survival rates and quality of life for individuals battling various forms of cancer.

According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.

Market Dynamics:

Driver:

Rising in cancer cases

Capecitabine, a chemotherapy medication, is widely used in the treatment of multiple cancer types, including breast, colorectal, and gastric cancers. Its oral administration, coupled with its ability to convert into an active form within the body, makes it a convenient and potent option for cancer therapy. The expanding pool of cancer patients necessitates increased access to treatment options like Capecitabine, thereby driving its market growth as a crucial therapeutic choice in combating the rising tide of cancer cases worldwide.

Restraint:

Increasing treatment costs

As healthcare expenses rise, including medication costs, affordability becomes a concern for patients and healthcare systems. Capecitabine, a chemotherapy drug used to treat various cancers, might become less accessible due to its higher cost, impacting patient adherence and healthcare budget constraints. The increasing financial burden on individuals and healthcare providers limits access to this medication, potentially hindering its widespread use and affecting treatment options for cancer patients.

Opportunity:

Growing acceptance of oral chemotherapy

As an oral medication, capecitabine offers patients more convenience, flexibility, and a better quality of life throughout treatment than standard intravenous chemotherapy. In addition, minimal hospital visits are required, and self-administration at home is an option, which simplifies healthcare delivery and lowers expenses. Moreover, the change in cancer treatment towards oral chemotherapy is indicative of an evolutionary change. Capecitabine, with its oral formulation, is leading this trend and has positioned itself well in the market by satisfying patient demand for more convenient and accessible treatment alternatives. Thereby, it will enhance market growth.

Threat:

Lack of Skilled Professionals

Administering chemotherapy, including drugs like Capecitabine, requires specialised knowledge and training. The shortage of proficient oncologists, nurses, and pharmacists capable of managing and overseeing chemotherapy procedures could impede the effective use and prescription of Capecitabine. This dearth of skilled professionals might result in suboptimal treatment, compromising patient outcomes, and potentially limiting the drug's utilization.

Covid-19 Impact

The COVID-19 pandemic had a notable effect on the overall economy. The pandemic caused many API manufacturing plants to close during this time, which presented the API business with a number of difficulties. Some of these were supply chain disruptions, issues in locating raw materials and packaging materials, and decreased operational capacity as a result of labour shortages. But when the COVID-19 situation worsened, there was a surge in the market for several medications, which raised the need for production-related APIs.

The breast cancer segment is expected to be the largest during the forecast period

The breast cancer segment is estimated to hold the largest share. Capecitabine, an oral chemotherapy drug, is widely utilized in various stages and types of breast cancer, including metastatic breast cancer and adjuvant therapy after surgery. Its effectiveness in inhibiting cancer cell growth and its oral administration convenience make it a preferred choice in breast cancer treatment regimens. As part of combination therapies or standalone treatment, Capecitabine's efficacy in targeting breast cancer cells has established its significance, cementing its position as a pivotal component in addressing the therapeutic needs of patients battling breast cancer.

The capsules segment is expected to have the highest CAGR during the forecast period

The capsules segment is anticipated to have lucrative growth during the forecast period. Capecitabine is commonly available in capsule form, offering a convenient oral administration route for patients undergoing chemotherapy. The capsules contain the active drug, facilitating precise dosing and ease of intake. Moreover, the capsule form of Capecitabine contributes substantially to its market presence, providing both medical professionals and patients with a convenient and efficient option for managing various cancer types, further solidifying its role in the pharmaceutical landscape.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to the prevalence of cancer and vulnerable geriatric population. Additionally, the region's large population base, particularly in countries like China, India, and Japan, offers a substantial patient pool, fostering market expansion. Moreover, collaborations between pharmaceutical companies, government initiatives to enhance cancer care, and the introduction of cost-effective generic versions further propel the accessibility and adoption of Capecitabine across the Asia-Pacific region.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities. Moreover, the region's robust healthcare infrastructure, advanced research facilities, and high prevalence of cancer contribute to the substantial utilisation of Capecitabine in the treatment of various cancer types, including breast and colorectal cancers. Favourable reimbursement policies and increasing investments in healthcare support the accessibility of Capecitabine, making North America a pivotal region in shaping the landscape of Capecitabine utilisation and market expansion.

Key players in the market

Some of the key players in the Capecitabine Market include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi, GSK plc, Pfizer Inc., Novartis AG, Lilly, Bayer AG, Merck & Co., Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Alkem Labs Ltd, Lupin, Armas Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Cipla Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Limited.

Key Developments:

In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.

In February 2021, Dr Reddy's Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.

Drug Types Covered:

  • Generic
  • Branded

Indications Covered:

  • Breast Cancer
  • Colorectal Cancer
  • Other Indications

Distribution Channels Covered:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Drug Formulations Covered:

  • Capsules
  • Tablets

End Users Covered:

  • Hospitals
  • Speciality Centres
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Capecitabine Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Generic
  • 5.3 Branded

6 Global Capecitabine Market, By Indication

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Colorectal Cancer
  • 6.4 Other Indications

7 Global Capecitabine Market, By Distribution Channel

  • 7.1 Introduction
  • 7.2 Hospital Pharmacy
  • 7.3 Retail Pharmacy
  • 7.4 Online Pharmacy

8 Global Capecitabine Market, By Drug Formulation

  • 8.1 Introduction
  • 8.2 Capsules
  • 8.3 Tablets

9 Global Capecitabine Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Speciality Centres
  • 9.4 Homecare
  • 9.5 Other End Users

10 Global Capecitabine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 F. Hoffmann-La Roche Ltd.
  • 12.2 Teva Pharmaceutical Industries Ltd.
  • 12.3 Mylan N.V.
  • 12.4 Sanofi
  • 12.5 GSK plc
  • 12.6 Pfizer Inc.
  • 12.7 Novartis AG
  • 12.8 Lilly
  • 12.9 Bayer AG
  • 12.10 Merck & Co., Inc.
  • 12.11 Aurobindo Pharma
  • 12.12 Sun Pharmaceutical Industries Ltd.
  • 12.13 Alkem Labs Ltd
  • 12.14 Lupin
  • 12.15 Armas Pharmaceuticals, Inc
  • 12.16 Dr. Reddy's Laboratories Ltd.
  • 12.17 Cipla Inc.
  • 12.18 Fresenius SE & Co. KGaA
  • 12.19 Hikma Pharmaceuticals PLC
  • 12.20 Intas Pharmaceuticals Limited

List of Tables

  • Table 1 Global Capecitabine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 3 Global Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 4 Global Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 5 Global Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 6 Global Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 7 Global Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 8 Global Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 9 Global Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 10 Global Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 11 Global Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 12 Global Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 13 Global Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 14 Global Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 15 Global Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 16 Global Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 17 Global Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 18 Global Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 19 Global Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 20 Global Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 21 North America Capecitabine Market Outlook, By Country (2023-2034) ($MN)
  • Table 22 North America Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 23 North America Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 24 North America Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 25 North America Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 26 North America Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 27 North America Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 28 North America Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 29 North America Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 30 North America Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 31 North America Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 32 North America Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 33 North America Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 34 North America Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 35 North America Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 36 North America Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 37 North America Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 38 North America Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 39 North America Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 40 North America Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 41 Europe Capecitabine Market Outlook, By Country (2023-2034) ($MN)
  • Table 42 Europe Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 43 Europe Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 44 Europe Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 45 Europe Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 46 Europe Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 47 Europe Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 48 Europe Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 49 Europe Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 50 Europe Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 51 Europe Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 52 Europe Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 53 Europe Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 54 Europe Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 55 Europe Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 56 Europe Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 57 Europe Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 58 Europe Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 59 Europe Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 60 Europe Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 61 Asia Pacific Capecitabine Market Outlook, By Country (2023-2034) ($MN)
  • Table 62 Asia Pacific Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 63 Asia Pacific Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 64 Asia Pacific Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 65 Asia Pacific Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 66 Asia Pacific Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 67 Asia Pacific Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 68 Asia Pacific Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 69 Asia Pacific Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 70 Asia Pacific Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 71 Asia Pacific Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 72 Asia Pacific Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 73 Asia Pacific Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 74 Asia Pacific Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 75 Asia Pacific Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 76 Asia Pacific Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 77 Asia Pacific Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 78 Asia Pacific Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 79 Asia Pacific Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 80 Asia Pacific Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 81 South America Capecitabine Market Outlook, By Country (2023-2034) ($MN)
  • Table 82 South America Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 83 South America Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 84 South America Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 85 South America Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 86 South America Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 87 South America Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 88 South America Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 89 South America Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 90 South America Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 91 South America Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 92 South America Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 93 South America Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 94 South America Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 95 South America Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 96 South America Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 97 South America Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 98 South America Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 99 South America Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 100 South America Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)
  • Table 101 Middle East & Africa Capecitabine Market Outlook, By Country (2023-2034) ($MN)
  • Table 102 Middle East & Africa Capecitabine Market Outlook, By Drug Type (2023-2034) ($MN)
  • Table 103 Middle East & Africa Capecitabine Market Outlook, By Generic (2023-2034) ($MN)
  • Table 104 Middle East & Africa Capecitabine Market Outlook, By Branded (2023-2034) ($MN)
  • Table 105 Middle East & Africa Capecitabine Market Outlook, By Indication (2023-2034) ($MN)
  • Table 106 Middle East & Africa Capecitabine Market Outlook, By Breast Cancer (2023-2034) ($MN)
  • Table 107 Middle East & Africa Capecitabine Market Outlook, By Colorectal Cancer (2023-2034) ($MN)
  • Table 108 Middle East & Africa Capecitabine Market Outlook, By Other Indications (2023-2034) ($MN)
  • Table 109 Middle East & Africa Capecitabine Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 110 Middle East & Africa Capecitabine Market Outlook, By Hospital Pharmacy (2023-2034) ($MN)
  • Table 111 Middle East & Africa Capecitabine Market Outlook, By Retail Pharmacy (2023-2034) ($MN)
  • Table 112 Middle East & Africa Capecitabine Market Outlook, By Online Pharmacy (2023-2034) ($MN)
  • Table 113 Middle East & Africa Capecitabine Market Outlook, By Drug Formulation (2023-2034) ($MN)
  • Table 114 Middle East & Africa Capecitabine Market Outlook, By Capsules (2023-2034) ($MN)
  • Table 115 Middle East & Africa Capecitabine Market Outlook, By Tablets (2023-2034) ($MN)
  • Table 116 Middle East & Africa Capecitabine Market Outlook, By End User (2023-2034) ($MN)
  • Table 117 Middle East & Africa Capecitabine Market Outlook, By Hospitals (2023-2034) ($MN)
  • Table 118 Middle East & Africa Capecitabine Market Outlook, By Speciality Centres (2023-2034) ($MN)
  • Table 119 Middle East & Africa Capecitabine Market Outlook, By Homecare (2023-2034) ($MN)
  • Table 120 Middle East & Africa Capecitabine Market Outlook, By Other End Users (2023-2034) ($MN)